Navigation Links
Shire's ELAPRASE(R) (idursulfase) Approved in Japan for the Treatment of Hunter Syndrome
Date:10/4/2007

BASINGSTOKE, England and CAMBRIDGE, Massachusetts, October 4 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ) announced today that Japan's Ministry of Health, Labour and Welfare has approved ELAPRASE, a human enzyme replacement therapy for the treatment of Hunter syndrome, for sale and marketing in Japan. Since its U.S. approval in July 2006, ELAPRASE is now approved for marketing and commercial distribution in 34 countries worldwide.

Hunter syndrome, also known as Mucopolysaccharidosis II (MPS II), is a rare, life-threatening genetic condition mainly affecting males that results from a deficiency in the lysosomal enzyme iduronate-2-sulfatase. Without this enzyme, cellular waste products accumulate in tissues and organs, which then begin to malfunction, leading to severe clinical complications and early mortality.

ELAPRASE, developed by Shire Human Genetic Therapies, Inc. (HGT) is the first and only enzyme replacement therapy approved for people suffering from Hunter syndrome. This medicine is given as a weekly infusion and is designed to replace the deficient iduronate-2-sulfatase enzyme.

As part of an agreement with Genzyme Corporation, Genzyme will manage sales and distribution of ELAPRASE in Japan.

"The approval of ELAPRASE in Japan is another important step in bringing this much-needed treatment to Hunter syndrome patients around the world," said Sylvie Gregoire, president of Shire HGT, the Shire business focused on genetic diseases. "We greatly appreciate the commitment and determination invested by the Japanese patients and their families who temporarily moved to the United States to participate in the ELAPRASE pivotal trial. Their participation in the trial facilitated a rapid approval of ELAPRASE, allowing it to now be available to Hunter syndrome patients in Japan."

Notes to editors

About ELAPRASE

ELAPRASE is a purified form of the lysosomal enzyme iduronate-2-sulfatase and is produced
'/>"/>

SOURCE Shire PLC
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. Genzyme acquistion of Bone Care approved, significant impact forecast
2. Japan on the rebound: Implications for Midwest
3. Japanese delegates highlight Wisconsin at BIO Chicago
4. Japanese telecom opens liason office at UW-Platteville
5. Promega, Japanese lab announce partnership
6. Japanese institute installs Imago system
7. Wisconsin biotechs plan Japan trade mission
8. Sonic Foundry makes Japanese version of lead product
9. OpGen forges agreement with Japanese importer
10. Japanese biotech is booming and linked with Midwest
11. Japans pharma mergers will trickle to the Midwest

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/19/2009)...FirstCall/ -- Omeros Corporation (Nasdaq: OMER ) ...e third quarter ended September 30, 2009. For the ...rted a net loss of $3.9 million, or $1.34 per shar...2.54 per share, for the same period in 2008. For t...ny reported a net loss of $15.5 million, or $5.29 ...
(Date:11/19/2009)...-FirstCall/ -- NeoStem, Inc. (NYSE Amex: NBS ), a...er to its shareholders, discussing the Company,s a...aceuticals Holdings, Inc. (CHBP), an integrated bi...ublic of China. The merger gives NeoStem a control.... Ltd., CHBP,s primary operating subsidiary and a ...
(Date:11/19/2009)...mber 19 MONITORING FORCE GmbH,anno...Flibanserin in the,indication treatment-relevant l...for orphan drug status designation with the Europe...nesia is a complication of the mainstay,treatment ...me of those,affected, since it may be disabling fo...
(Date:11/19/2009)...ne Synthesis Companies Form International Gene Syn...ces in Risk Reduction ,Five Member Companies Rep...city , (PRWEB) November 1...synthesis companies today announced agreement that...omote biosecurity in the gene synthesis industry. ...
Breaking Biology Technology:Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 2Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 3Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 4Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 5Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 6Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 7Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 8NeoStem Outlines to Shareholders Near-term and Long-term Business Strategies Following Acquisition of Chinese Pharmaceutical Company 2NeoStem Outlines to Shareholders Near-term and Long-term Business Strategies Following Acquisition of Chinese Pharmaceutical Company 3MONITORING FORCE GmbH Requests Acknowledgment of Flibanserin as "Orphan Drug" 2World's Top Gene Synthesis Companies Establish Tough Biosecurity Screening Protocol 2World's Top Gene Synthesis Companies Establish Tough Biosecurity Screening Protocol 3World's Top Gene Synthesis Companies Establish Tough Biosecurity Screening Protocol 4
...lant to Provide an Attractive Domestic Alternative...y 18 Fulcrum BioEnergy, Inc.,today announced that...n,with its plans to build one of the first commerc...icipal solid waste to ethanol. The plant will,proc...olutionizing waste,disposal while creating a much ...
...ignificantly Strengthens Teva,s Market Leadership ...n Key Global Markets, Acquisition Expected to Be ...RUSALEM and MONTVALE, N.J., July 18 Teva,Pharmace...harmaceuticals,Inc. (NYSE: BRL ) announced today ... which Teva will acquire Barr, the fourth largest ...
... CAMBRIDGE, Mass., July 17, 2008 -- The Defense A...ed a $1.2 million grant to an interdisciplinary te...ace enhanced Raman scattering (SERS) for the first... phases of the development program are completed, ... million in funding. , Ken Crozier, Assistant Pro...
Other Biology Technology:Fulcrum BioEnergy Announces Plans to Build One of the First Commercial-Scale Ethanol Plants Using Municipal Solid Waste as Feedstock 2Fulcrum BioEnergy Announces Plans to Build One of the First Commercial-Scale Ethanol Plants Using Municipal Solid Waste as Feedstock 3Teva to Acquire Barr 2Teva to Acquire Barr 3Teva to Acquire Barr 4Teva to Acquire Barr 5Teva to Acquire Barr 6Teva to Acquire Barr 7Teva to Acquire Barr 8DARPA awards research team $1.2M grant to study surface enhanced Raman scattering 2
(Date:11/20/2009)...igin of biological molecules like RNA and DNA is h...from simple precursors. Now, in a study appearing ...nstructed one of the earliest evolutionary steps y...subunits using nothing but warm water. , Many r...iological molecules present, before DNA and protei...
(Date:11/20/2009)... - Bacteria possess an ingenious mechanism for pre... the cell. This is the new finding of a team of bi...e sciences research institute in Flanders, Belgium... scientists made this discovery by modifying the D... By means of this model organism, they have uncove...
(Date:11/20/2009)...Research Center (ERC) has been awarded a grant fro...ethods of recovering and reusing the heat that wou...ression process in a carbon capture system. The go... capture and sequestration, or storage (CCS), and ...emitted into the atmosphere by coal-fired power pl...
Breaking Biology News(10 mins):Biologists discover bacterial defense mechanism against aggressive oxygen 2Lehigh receives grant to reduce cost of carbon capture at coal-fired power plants 2Lehigh receives grant to reduce cost of carbon capture at coal-fired power plants 3Ferns took to the trees and thrived 9095 1Ferns took to the trees and thrived 9095 2iMedExchange Launches Health Policy Resource Center 50653 1iMedExchange Launches Health Policy Resource Center 50653 2WellPoints Contribution To Drug Formulary Evaluation Standards Highlighted in ISPOR Publication 50651 1WellPoints Contribution To Drug Formulary Evaluation Standards Highlighted in ISPOR Publication 50651 2WellPoints Contribution To Drug Formulary Evaluation Standards Highlighted in ISPOR Publication 50651 3
... scientists offer a compendium of air pollution re...n humans and the environment, while addressing the... fire as a land management tool. , The 686-page b...rts from various science disciplines who studied s...sia, and Australia from prehistoric times to the p...
... toward winter, many people will begin to experien...evastating. , About 6 percent of the U.S. popula...SAD, a sometimes-debilitating depression that begi...rers may even find it difficult to get out of bed ... understood, is often treated with "light therapy,...
...t cheap piece of scrap iron before you toss it in .... Someday soon, much of the world might also. , Z...eering, recently concluded a five-year research pr...versity in Shanghai used two million pounds of iro... , The project, carried out in Shanghai, was the ...
Other Biology News:Book explores global implications of wildland fire smoke 2Seasonal affective disorder may be linked to genetic mutation, study suggests 2A green future for scrap iron 2A green future for scrap iron 3
Rabbit Anti-Human Naked1 Polyclonal Antibody, Unconjugated from Cell Signaling Technology
Rabbit Anti-NF-kB p65, phospho (Ser345) Antibody, Unconjugated from Spring Bioscience
Anti-NSP-C (Neuroendocrine-Specific-Protein) Monoclonal Antibody, Unconjugated, Clone RNL-4 from CHEMICON
Rabbit Anti-Human ADAMTS-4, disintegrin-like domain Antibody, Unconjugated from CHEMICON
Biology Products: